Medline (MDLN) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Medline is the larger company by market cap ($47.70 billion vs $14.62 billion), about 3.3 times the size. On valuation, Solventum trades at a lower forward P/E (11.9x vs 22.5x for Medline). Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDLN | SOLV |
|---|---|---|
| Share price | $35.45 | $85.88 |
| Market cap | $47.70B | $14.62B |
| 1-day change | -0.28% | -1.33% |
| YTD return | -15.25% | +8.38% |
| 1-year return | — | +19.01% |
| P/E ratio (TTM) | 88.63 | 10.51 |
| Forward P/E | 22.48 | 11.88 |
| EPS (TTM) | $0.40 | $8.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $28.43B | $8.32B |
| Revenue growth (YoY) | — | +0.86% |
| Net income (latest FY) | $1.16B | $1.56B |
| Gross margin | 26.44% | 53.47% |
| Operating margin | 7.78% | 26.20% |
| Net margin | 4.08% | 18.69% |
| 52-week high | $50.88 | $94.16 |
| 52-week low | $31.49 | $62.38 |
| Distance from 52-week high | -30.32% | -8.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +25.53% | +9.82% |
| Average volume | 7.61M | 1.02M |
| Shares outstanding | 877.35M | 170.22M |
| Employees | 45,000 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline is about 3.3 times larger than Solventum by market value ($47.70B vs $14.62B).
- Medline trades at a higher earnings multiple (88.6x vs 10.5x trailing P/E).
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 4.1 cents for Medline.
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
MDLN vs SOLV FAQ
Which is bigger, Medline or Solventum?
Medline (MDLN) is larger, with a market capitalization of $47.70B compared with $14.62B for Solventum (SOLV).
Which has the lower P/E ratio, MDLN or SOLV?
SOLV has the lower trailing P/E at 10.5, versus 88.6 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Medline and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.